AUA 2017: Paravertebral Block for Percutaneous Nephrolithotomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Study

Boston, MA ( Dr. Baldea and a group of urologists and anesthesiologists from Loyola University in Chicago conducted a clinical trial to investigate the efficacy of paravertebral block (PVB) for percutaneous nephrolithotomy (PCNL). The primary objective in this study was to compare subjective and objective pain outcomes with a fentanyl PVB.

Visual analog pain scores decreased from 3 to 2.7 to 2 at 12- and 24-hours postoperatively. In addition, the total intravenous morphine equivalent dose and PCA pump demand was approximately 13% lower in the PVB group. Furthermore, significant differences (p < 0.001) were found for time to first analgesic administration (120 vs. 20 minutes, PVB and placebo, respectively) and rate of supplemental PO narcotic use (30 vs. 62%, PVB and placebo, respectively). Interestingly, there was a near 20% in the amount of anti-emetics required for the PVB group.

Following the presentation, Dr. Baldea commented that a majority of PCNLs were performed with lower pole access and there was no significant difference in pain outcomes with respect to variable access sites. In addition, a single anesthesiologist supervised and performed a majority (>80%) of the PVBs; however, PVB experience is an important consideration if it is to be utilized for PCNL.

Presented By: Dr. Kristin G. Baldea, MD

Author(s): Kristin G. Baldea, Grace Delos Santos, Chandy Elilimoottil, Ahmer Farooq, Elizabeth R. Mueller, Scott Byram, Thomas M.T. Turk

Affiliation: Loyola University, Chicago, IL University of Michigan, Ann Arbor, MI

Written By: Daniel Lama for

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.